5 (627) In stock
In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
A primer on recent developments in cancer immunotherapy, with a
What is neoantigen-based therapy?
Targeting neoantigens for cancer immunotherapy
Cancer vaccines are showing promise. Here's how they work.
PDF) Immunotherapy in prostate cancer: current state and future
When neoantigen expression is low, the T cells won't go
Nanomaterials in tumor immunotherapy: new strategies and
Cancer vaccines: Building a bridge over troubled waters. - Abstract - Europe PMC
Developing neoantigen-targeted T cell–based treatments for solid
What is neoantigen-based therapy?
Neoantigens: promising targets for cancer therapy
Developing neoantigen-targeted T cell–based treatments for solid tumors
